Skip to main content

Garnering Knowledge Gains for Treatment of Advanced Renal Cell Carcinoma

An educational enduring live meeting series and online activity provided by i3 Health has demonstrated knowledge gains encompassing the nurse's perspective of evolving treatment paradigms in advanced renal cell carcinoma (RCC). Kidney cancer is among the top 10 most common cancers in the United States, accounting for approximately 4% of all cancer diagnoses in the US. The American Cancer Society predicted that in 2022, 79,000 new cases of kidney cancer would be diagnosed, with 13,920 of these ca...

Continue reading

FDA Approves Single-Agent Pembrolizumab as Adjuvant Therapy for Renal Cell Carcinoma

The FDA has approved pembrolizumab (Keytruda®, Merck) for the adjuvant treatment of patients with renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy or following nephrectomy with resection of metastatic lesions."Patients with renal cell carcinoma who undergo nephrectomy [had] no options for adjuvant therapy to reduce the risk of recurrence that have high levels of supporting evidence [prior to this approval]," wrote Toni K. Choueiri, MD, Director of the Ki...

Continue reading

The Changing Treatment Landscape for Renal Cell Carcinoma: Bradley McGregor, MD

Within the last few years, treatment of renal cell carcinoma has improved dramatically, with FDA approvals of several agents and numerous others in development. In this interview, Bradley McGregor, MD, Clinical Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard Medical School, highlights these exciting developments and sheds light on the additional progress that is underway for the treatment of renal cell carcinoma. Onc...

Continue reading

FDA Approves Lenvatinib and Pembrolizumab Combination for Advanced Renal Cell Carcinoma

The FDA has granted approval to the combination of lenvatinib (Lenvima®, Eisai) plus pembrolizumab (Keytruda®, Merck) for the treatment of patients with advanced renal cell carcinoma (RCC) who are undergoing first-line treatment. "Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced RCC," wrote Robert Motzer, MD, Jack and Dorothy Byrne Chair in Clinical Oncology at Memorial Sloan Kettering Cancer Center, and colleagues, in their publication of results of the p...

Continue reading

Exploring Treatment Options for Patients With Renal Cell Carcinoma: Bradley McGregor, MD, and Robert Motzer, MD

In 2021, an estimated 76,080 new cases of kidney cancer will be diagnosed. Among those cases, the majority will be renal cell carcinomas (RCC). In this excerpt of the transcript from their continuing medical education/nursing continuing professional development (CME/NCPD)–approved activity, Expert Guidance on New Advances in Renal Cell Carcinoma, Bradley McGregor, MD, Clinical Director of the Lank Center of Genitourinary Oncology at the Dana-Farber Cancer Institute, and Robert Motzer, MD, Chair ...

Continue reading

Renal Cell Carcinoma: Subtype, Site of Metastasis Impacts Survival

There are over a dozen histologic variants of renal cell carcinoma (RCC); therefore, each tumor can vary widely based on genetic, pathologic, and clinical characteristics. The most common histologic variants of RCC include clear cell RCC, papillary RCC, and chromophobe RCC. In a recent study, results of which are now published in JAMA Network Open, researchers found that disease spread for metastatic RCC may vary based on histologic variant, and the location of disease spread is associated with ...

Continue reading

Nivolumab Shows Long-Term Efficacy in Advanced RCC

In patients with previously treated advanced renal cell carcinoma (RCC), nivolumab significantly increases overall survival and response rates compared with everolimus, according to the final updated analysis of the phase 3 CheckMate 025 trial. A randomized, open-label trial, CheckMate 025 enrolled 821 patients with advanced RCC previously treated with antiangiogenic therapies. Patients were randomized in a 1:1 ratio to receive 3 mg/kg of nivolumab intravenously every two weeks or 10 mg of evero...

Continue reading

Advances in the Personalized Management of RCC With Brian I. Rini, MD, FACP

Based on recent estimates, kidney cancer accounts for approximately 4% of all cancer diagnoses in the United States. An estimated 65,300 new cases are reported each year and more than 14,000 people die of the disease. Renal cell carcinoma (RCC), which comprises nearly 90% of all kidney cancers, is characterized by a lack of early warning signs, diverse clinical manifestations, and resistance to radiation and chemotherapy. As a result of its often asymptomatic presentation, many patients present ...

Continue reading